HomeGRAL • NASDAQ
add
Grail Inc
Previous close
$28.61
Day range
$23.34 - $28.40
Year range
$13.41 - $28.40
Market cap
873.28M USD
Avg Volume
1.08M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Revenue | 28.65M | 38.27% |
Operating expense | 175.74M | -12.27% |
Net income | -125.69M | 85.90% |
Net profit margin | -438.67 | 89.80% |
Earnings per share | -3.50 | — |
EBITDA | -125.27M | 18.72% |
Effective tax rate | 27.10% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 853.55M | — |
Total assets | 3.12B | — |
Total liabilities | 530.32M | — |
Total equity | 2.59B | — |
Shares outstanding | 33.60M | — |
Price to book | 0.37 | — |
Return on assets | -12.88% | — |
Return on capital | -15.14% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2024info | Y/Y change |
|---|---|---|
Net income | -125.69M | 85.90% |
Cash from operations | -104.58M | 33.60% |
Cash from investing | -971.00K | 68.36% |
Cash from financing | 0.00 | -100.00% |
Net change in cash | -105.29M | -21.33% |
Free cash flow | -36.90M | — |
About
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Founded
2015
Headquarters
Website
Employees
1,170
